PFA Technology Empowers County-Level Healthcare: Shineyo Medical's 'Pulse Toward the Future' Forum Successfully Concludes

On January 17, 2026, in积极响应国家《医疗卫生强基工程实施方案》, ShineyoMedical joined hands with Pusheng Medical Group to hold"‘Pulse to the Future’ Atrial Fibrillation New Technology Diagnosis and Treatment County Development Forum"This forum, themed "Innovation in PFA Ablation Technology," delved into the significant transformation this technology has brought to the diagnosis and treatment model of atrial fibrillation. The meeting covered a range of clinically relevant topics, including recommendations for anesthesia protocols during PFA procedures, perioperative management, and standardized training for catheter operation. Multiple authoritative experts in China, drawing on extensive clinical experience, expressed strong recognition of the clinical safety, efficacy, and operational optimization of the RhythPulse®️-PFA Multi-Channel Pulsed Field Ablation System developed by ShineyoMedical, while also providing valuable suggestions for further system enhancements.

The meeting was opened with an address by Wang Pengju, Chairman of Pusheng Medical.

He pointed out that in the field of cardiac electrophysiology ablation, the application of PFA technology in China is becoming increasingly widespread, with clinical exploration continuously deepening and practical experience constantly accumulating. As a practitioner and leader in the innovation of domestically produced medical devices, ShineyoMedical firmly believes that PFA technology will strongly drive the diagnosis and treatment of arrhythmia in China to new heights. Moreover, the rise of domestic devices and the process of import substitution will lead the industry into a new era of precision, safety, and efficiency, bringing good news to countless patients.

Professor Wang Yuanlong from the Sixth People's Hospital of ShanghaiYesExperience Sharing on Operating the RhythPulse®-PFA Pulsed Field Ablation System Under Different Anesthesia ProtocolsConduct an in-depth analysis, combining the clinical application of the RhythPulse® Pulse Ablation System, breaking down key technical application nodes, and systematically elaborating on the value of the ShineyoMedical PFA catheter in atrial fibrillation surgeries.

Professor Wang first analyzed the current status of global PFA anesthesia options, pointing out that general anesthesia is the primary method commonly used abroad, while in Chinese clinical practice, conscious sedation is more frequently adopted, leading to a unique debate between "general anesthesia versus local anesthesia." Behind this difference lies the real contradiction between the relative shortage of anesthesiologist resources in China and the continuously increasing volume of atrial fibrillation surgeries.

In response to this core issue, Professor Wang focused on exploring the clinical value of different sedation protocols. The latest research data shows that, under standardized operation, deep sedation and conscious sedation protocols can significantly optimize procedural efficiency and save medical resources without compromising the success rate and safety of the surgery.

In the final session, Professor Wang systematically shared clinical application experiences of the RhythPulse®-PFA pulsed ablation system, drawing from real case studies at the Sixth People's Hospital of Shanghai. The RhythPulse®-PFA system employs a bipolar biphasic square wave design, offers multiple selectable ablation templates, and is fully compatible with both general anesthesia and local anesthesia protocols. This design allows physicians to flexibly develop personalized anesthesia strategies based on the patient’s overall condition. For instance, general anesthesia can enhance patient compliance and procedural stability in special populations such as obese patients; for those unsuited for general anesthesia, the system can still achieve safe and efficient ablation under sedation or local anesthesia. Intraoperative and postoperative follow-ups indicate that patients tolerated the procedure well without significant discomfort. He noted that the flexibility and safety of the RhythPulse®-PFA pulsed ablation system provide reliable technical support for atrial fibrillation ablation across various clinical scenarios.

This lecture focuses on clinical practical needs, promotes the consensus on the optimization of PFA anesthesia strategies, and provides important reference for safely and efficiently carrying out new technologies under resource constraints, helping to improve the level of atrial fibrillation diagnosis and treatment in China.

Professor Xie Qiying from Xiangya Hospital, Central South UniversityYes"Application Technology Exploration and Advantages of RhythPulse®-PFA Catheter Combined with 3D System"Conduct an in-depth interpretation and thoroughly analyze the innovative pathways and clinical value of technological integration.

Professor Xie systematically reviewed the development process of catheter ablation energy for atrial fibrillation and, based on cutting-edge simulation studies, analyzed the impact of different catheter tip designs on ablation efficiency and safety. Against this background,ShineyoMedical RhythPulse®-PFA SystemWith its full range of sizes, unique patented design, and excellent adaptability to pulmonary vein anatomy, it demonstrates the potential to achieve efficient and continuous transmural injury, providing clinicians with a flexible and reliable instrument option.

Secondly, Professor Xie further explored and revealed the significant value of combining PFA technology with a three-dimensional electroanatomical mapping system. Clinical studies have confirmed that the combination of the two can significantly reduce radiation dose and fluoroscopy time during surgery, effectively ensuring the safety of both doctors and patients. Meanwhile, the integrated "mapping-ablation" workflow reduces the number of catheter exchanges, improving surgical efficiency and smoothness.RhythPulse®-PFA SystemIt has achieved compatibility with mainstream 3D systems, providing a comprehensive solution for precise and visual atrial fibrillation ablation.

Finally, Professor Xie demonstrated the advantages of this integrated solution through actual cases and clinical data. Under the guidance of a three-dimensional electroanatomical mapping system, the RhythPulse®-PFA catheter can achieve precise pulmonary vein isolation, significantly reduce radiation exposure, optimize surgical procedures, and ensure stable acute procedural success rates. This exploration provides strong clinical evidence for PFA technology to enable safer, more efficient, and visualized precision treatment.

In summary, this presentation fully demonstrates the comprehensive advantages of the RhythPulse®-PFA system in technical design and clinical application through cutting-edge research analysis and clinical practice sharing, providing important academic references and practical directions for promoting the standardized development of PFA technology and the improvement of atrial fibrillation treatment levels.

In"Advantages and Perioperative Management of RhythPulse®-PFA Pulse Ablation System in the Treatment of Atrial Fibrillation"In the sharing,Professor Chen Panpan from Zhengzhou Seventh People's HospitalThe core value and clinical application standards of this innovative solution are systematically introduced, providing a practical guide for the standardized application of the technology.

She first explained the design advantages of the system: The RhythPulse® catheter is available in full specifications ranging from 10-25mm, with the exclusive 10mm catheter usable as a large focal catheter. Its central helical structure and patented single-sided coated electrode design enable better tissue contact and targeted energy delivery, effectively reducing ineffective discharges. The accompanying ShineRhythm® ablation generator features R-wave synchronization, impedance feedback, and optional electrode discharge functions, collectively enhancing the safety and precision of the procedure.

In addition, the 10mm large focal catheter can serve as an alternative for linear ablation, enabling more efficient and safer point-by-point or linear ablation while balancing the operational efficiency of 3D modeling and pulmonary vein isolation. It is the preferred device for transitioning from traditional radiofrequency ablation (RFA) to pulsed field ablation (PFA).

Professor Chen then shared key clinical validation data: a prospective multicenter clinical trial confirmed that the system demonstrated excellent safety, with no serious adverse events related to the device; it also achieved a 100% immediate pulmonary vein isolation success rate and an 85.07% success rate at 12 months post-operation, reaching an internationally advanced level of efficacy.

She emphasized the standardization ofPerioperative Management Process, including patient screening, standardized ablation strategies (such as recommending at least 8 sets of ablations for each pulmonary vein), prevention and management of complications (such as the prevention and treatment of hemolysis and kidney injury), and key points for postoperative follow-up, providing systematic guidance for the safe and efficient performance of surgeries in clinical practice.

Finally, through actual case studies, Professor Chen demonstrated how the system flexibly and accurately completes pulmonary vein isolation and linear ablation under 3D mapping guidance, achieving smooth operations of modeling, mapping, and ablation with a single catheter. She concluded that the RhythPulse®-PFA system, with its innovative design, proven clinical data, and comprehensive perioperative management solutions, offers a reliable and highly efficient full-range option for pulsed field ablation treatment of atrial fibrillation.

In the exhibition area, ShineyoMedical specially set up a surgical simulation demonstration zone, where the RhythPulse®-PFA pulsed electric field ablation system was displayed, including the RhythPulse® ablation catheter and the配套的ShineRhythm® ablation instrument. Combined with a three-dimensional system, the PFA simulator highly replicates the real surgical environment, allowing participating representatives to experience device operation firsthand and gain an intuitive understanding of the entire process and technical advantages of pulsed electric field ablation.

The successful hosting of this "PFA Ablation Technology Innovation" symposium not only built an efficient communication platform for top experts and frontline clinicians in the PFA field in China, but also promoted the standardized popularization and clinical application transformation of pulsed field ablation technology.

RhythPulse®-PFA Pulse Ablation System Provides a More Precise and Efficient Technical Pathway for AF Treatment

ShineyoMedical insists on using technological innovation to enhance the capabilities of grassroots healthcare, providing clinical settings with products that are safer, more efficient, and better suited to the needs of Chinese doctors. This significantly lowers the equipment threshold and operational costs for grassroots institutions, facilitating the delivery of high-quality services at the grassroots level, fully demonstrating the social responsibility and mission of China-produced medical device enterprises.

In the future, ShineyoMedical will continue to focus on the forefront of medical technology, constantly advancing product iteration and technological breakthroughs, developing more safe and practical medical devices, and promoting the diagnosis and treatment of cardiovascular diseases towards a more precise, safer, and more accessible direction. It will provide solid support for patients' health and contribute positively to the advancement of the medical industry.

【ShineyoMedical RhythPulse®-PFA System】

ShineyoMedical's RhythPulse®-PFA System is the first approved Pulse Field Ablation (PFA) system in China that integrates multi-channel, large focal, and targeted ablation, primarily used for treating drug-refractory and recurrent atrial fibrillation and other forms of rapid arrhythmia. Its core advantages include:

Large Focal Design:Using the world's first 10mm ring ablation catheter, a single discharge can cover a lesion area with a diameter of 10mm, increasing the ablation efficiency by more than three times compared to traditional technology.

Targeted Ablation Technology:Equipped with an intelligent proximity detection module, it monitors the contact status between the electrode and myocardial tissue in real time, reducing the risk of hemolysis caused by ineffective discharges, and decreasing postoperative plasma free hemoglobin content by 50%.

Excellent Clinical Validation:In the clinical trial of 151 cases, the immediate success rate was 100%, and the success rate of atrial fibrillation treatment at 12 months post-operation reached 85.07%, achieving internationally leading standards.